Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BPH Global's revenue for the
six
months ended in Dec. 2025 was A$1.38 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.68 Mil.
BPH Global's Revenue per Share for the
six
months ended in Dec. 2025 was A$0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00.
Warning Sign:
BPH Global Ltd revenue per share has been in decline over the past 3 years.
During the past 3 years, the average Revenue per Share Growth Rate was -75.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, BPH Global's highest 3-Year average Revenue per Share Growth Rate was 168.80% per year. The lowest was -99.30% per year. And the median was 66.00% per year.
BPH Global (ASX:BP8) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
BPH Global Revenue Related Terms
BPH Global Revenue Historical Data
* Premium members only.
The historical data trend for BPH Global's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BPH Global's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BPH Global Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BPH Global's Revenue distribution charts can be found below:
* The bar in red indicates where BPH Global's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$1.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BPH Global (ASX:BP8) has a Revenue of A$1.68 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on BPH Global and its competitors.
Is BPH Global's Revenue too high?
BPH Global's current Revenue is A$1.68 Mil.
How does BPH Global's Revenue compare to ZTS and UTHR?
BPH Global's Revenue of A$1.68 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on BPH Global and its competitors. BPH Global's current Revenue is A$1.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BPH Global stock overvalued right now?
BPH Global (ASX:BP8) has a current Revenue of A$1.68 Mil. The current Revenue is A$1.68 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For BPH Global (ASX:BP8), the current Revenue is A$1.68 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BPH Global Ltd is a plant-focused biotechnology company with a focus on producing foods, health, and cosmetic products that deliver Traditional Chinese Medicine (TCM)-based health outcomes. It focuses on the research, development, production, and commercialization of TCM products, including bird's nest, seaweeds, and sea plants, which serve as sustainable plant-based protein sources and ingredients for food, nutrition, healthcare, cosmetics, and personal care industries. The company's geographical segment includes Australia, Indonesia, and China. The company's products comprise raw and processed bird's nest, sea grapes (Caulerpa lentillifera), and other seaweeds and sea plants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BP8 has been successfully added to your 
